In summary, using a clinically approved and widely employed SMO inhibitor in both the Hesx1Cre/+;Ctnnb1loxex3/+ mice and a human xenograft model, our research demonstrates that the inhibition of the SHH pathway has a tumour-promoting effect. This evidence concerns the gene SMO and neoplasm.